motor neurone disease glutathione transferase

motor neurone disease glutathione transferase transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases The role of glutathione S-transferases

Name: motor neurone disease glutathione transferase transferases: substrates, inihibitors and pro-drugs in cancer and neurodegenerative diseases The role of glutathione S-transferases
Brand: condeoeiras.edu.pt
SKU: 66720328918
Price: 22.30 USD
Availability: InStock
Rating: 4.882000000000001 (27 reviews)

The role of glutathione S transferases in human disease pathogenesis and their current inhibitors PMC Neuroprotection against Aminochrome Neurotoxicity: Glutathione Transferase M2 2 and DT Diaphorase Oxytosis Ferroptosis in Neurodegeneration: the Underlying Role of Master Regulator Glutathione Peroxidase 4 (GPX4) Molecular Neurobiology Springer Nature Link The Role of Glutathione Metabolism in Chronic Illness Development and Its Potential Use as a Novel Therapeutic Target Cureus Frontiers Glutathione and neurodegenerative diseases: immunopharmacological implications Ferroptosis regulation through Nrf2 and implications for neurodegenerative diseases Archives of Toxicology Springer Nature Link

SKU: 66720328918 · From condeoeiras.edu.pt

4.9

USD22.30 USD43.30

Pay in 4 interest-free payments of $5.58 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 8 - Aug 13

Description

Protein restriction and cancer

PMC 2643293

*Correspondence: Shou-Dong Guo, [email protected] These authors have contributed equally to this work This article was submitted to Lipid and Fatty Acid Research, a section of the journal Frontiers in Physiology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

Structured evidence overview Conclusions Strongest clinical signal: prevention of oxaliplatin-induced peripheral neuropathy, where IV GSH 1,500 mg/m2 before oxaliplatin reduces clinically significant neurotoxicity without compromising antitumor efficacy